Packaged food stocks have significantly underperformed pharmaceutical stocks over the past year, driven largely by concerns over GLP-1 weight-loss drugs impacting food demand. While Eli Lilly's stock soared 74%, many food companies like Campbell's and General Mills saw declines. However, some food stocks like Kraft Heinz and Hershey have shown gains this year, and ETFs tracking food and pharmaceuticals reveal a more nuanced picture than the broad "food so hated" label suggests. Investors should be cautious as the GLP-1 impact remains uncertain, and some food stocks are recovering, indicating the sentiment gap may be closing rather than presenting a clear buying opportunity.
Morgan Stanley increased its price target for Eli Lilly to $1,430 from $1,419, maintaining an Overweight rating. This new target implies a potential upside of about 20.8% from the current share price of around $1,184. The adjustment reflects updated ...
Eli Lilly is rapidly growing its obesity and diabetes treatment portfolio, with its tirzepatide-based drugs Mounjaro and Zepbound generating nearly $15 billion in revenue and showing strong year-over-year growth of 91% and 46%, respectively. This gro...
Eli Lilly's most profitable stock entry points were during less hyped events like the 2008 ImClone acquisition and the 2014 Trulicity approval, yielding returns over 2,000%. In contrast, buying at the peaks of hype around blockbuster drugs Mounjaro a...
Eli Lilly (LLY) is recommended as a Strong Buy due to its attractive valuation and role as a diversification play for portfolios heavily invested in AI. Trading at about 24 times its 2027 earnings estimates, the stock is seen as premium but not overp...
Eli Lilly's stock is predicted to rise nearly 19% over the next year, driven by rapid growth in its oncology, immunology, and neuroscience drug portfolios, which grew 121% year-over-year last quarter. While known for weight loss drugs like Mounjaro a...
